Back to all studies
CompletedACTRN12618001042235

clinical study evaluating the efficacy and safety of R-107 for treatment-resistant depression.

This study is completed. It focuses on depression and currently lists study information in Australia, New Zealand, Singapore, and Taiwan, Province Of China.

DepressionDrugFrom 18 Years to 80 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What the source says

The registry describes this research topic: “A Phase 2 clinical study evaluating the efficacy and safety of R-107 for the Treatment of treatment-resistant depression”. This is an interventional study. The registry lists a target sample size of 150. Recruitment status at the registry update of 2022-11-08: completed. Read the original description and eligibility criteria, and confirm the practical details with the study team.

What should you check before joining?

Check the full criteria in the official source. Ask the team to confirm recruitment, locations, visits, risks and participation requirements.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateMay 30, 2019
Recruitment status
Completed
Enrollment listed in the registry
168
Sponsor
Douglas Pharmaceuticals Ltd.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Australia, New Zealand, Singapore, ...
Age range
From 18 Years to 80 Years
Official registry ID
ACTRN12618001042235
Official title
A Phase 2a Proof-of-Concept Study of R-107 for the Treatment of Refractory Major Depressive Disorder

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: ACTRN12618001042235. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Australia · 7 sites
  • Royal Prince Alfred Hospital
    Camperdown
    Site status: Not listed — confirm with the team
  • Gold Coast University Hospital
    Southport
    Site status: Not listed — confirm with the team
  • Lyell McEwin Hospital
    Elizabeth Vale
    Site status: Not listed — confirm with the team
  • Peninsula Private Hospital - Frankston
    Frankston
    Site status: Not listed — confirm with the team
  • Epworth Rehabilitation Camberwell
    Camberwell
    Site status: Not listed — confirm with the team
  • Albert Road Clinic
    Melbourne
    Site status: Not listed — confirm with the team
  • South Eastern Private Hospital
    Noble Park
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with depression; age range: From 18 Years to 80 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Douglas Pharmaceuticals Ltd., which appears to be another type of organization. The listed contact or investigator is Belinda Williams. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me